




RealRate

PHARMACEUTICAL 2019

Oncotelic Therapeutics Inc
Rank 344 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 7.3% points. The greatest weakness of Oncotelic Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 199% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	799
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,161
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	265
Other Revenues	0
Property and Equipment	0
Research and Development	815
Selling, General and Administrative Expense	2,187

Output Variable	Value in 1000 USD
Assets	799
Liabilities	1,161
Expenses	3,002
Revenues	0
Stockholders Equity	-362
Net Income	-2,737
Comprehensive Net Income	-2,737
BaseVar	2,614
ECR before Limited Liability	-360%
Economic Capital Ratio	50%